Entera Bio Ltd.
Latest From Entera Bio Ltd.
OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.
Returns for the 36 biopharma firms that went public in the first half of 2018 – including 14 in June alone – averaged 20.9%, stabilizing after a dip earlier in the year. But while drug developer returns have been on a rollercoaster ride, they're doing better than broader stock indices.
Public Company Edition: Kiniksa, Scholar Rock and Iterum launch the most recent US IPOs and at least five more drug developers join the queue. Also, Polyphor go public in Switzerland, Valeant and Ligand sell notes, and MyoKardia led recent follow-on offerings.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Middle East
- Parent & Subsidiaries
- Entera Bio Ltd.
- Senior Management
Phillip Schwartz , PhD, CEO
Mira Rosenzweig, CFO
Miriam Blum, PhD, CMO
- Contact Info
Entera Bio Ltd.
Minrav Building, 5th Fl.
P.O. Box 12117 Jerusalem, 91220
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.